Our top pick for
Taiwan Liposome Company, Ltd is a biotechnology business based in the US. Taiwan Liposome Company shares (TLC) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||$4.07 - $8.50|
|50-day moving average||$5.73|
|200-day moving average||$5.00|
|Wall St. target price||$12.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.51|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$101.9 million|
|Gross profit TTM||$101.9 million|
|Return on assets TTM||-40.32%|
|Return on equity TTM||-124.06%|
|Market capitalisation||$256.9 million|
TTM: trailing 12 months
There are currently 2,529 Taiwan Liposome Company shares held short by investors – that's known as Taiwan Liposome Company's "short interest". This figure is 2379.4% up from 102 last month.
There are a few different ways that this level of interest in shorting Taiwan Liposome Company shares can be evaluated.
Taiwan Liposome Company's "short interest ratio" (SIR) is the quantity of Taiwan Liposome Company shares currently shorted divided by the average quantity of Taiwan Liposome Company shares traded daily (recently around 25290). Taiwan Liposome Company's SIR currently stands at 0.1. In other words for every 100,000 Taiwan Liposome Company shares traded daily on the market, roughly 100 shares are currently held short.
However Taiwan Liposome Company's short interest can also be evaluated against the total number of Taiwan Liposome Company shares, or, against the total number of tradable Taiwan Liposome Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Taiwan Liposome Company's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Taiwan Liposome Company shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Taiwan Liposome Company shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Taiwan Liposome Company.
Find out more about how you can short Taiwan Liposome Company stock.
We're not expecting Taiwan Liposome Company to pay a dividend over the next 12 months.
Over the last 12 months, Taiwan Liposome Company's shares have ranged in value from as little as $4.07 up to $8.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Taiwan Liposome Company's is 0.952. This would suggest that Taiwan Liposome Company's shares are less volatile than average (for this exchange).
Taiwan Liposome Company, Ltd. , a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain. The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.